Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.82 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | GABRP | O00591 | 1/20 | 0.65 |
| ▸ | GABRD | O14764 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | KLK3 | P07288 | 1/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.65 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.65 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.65 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035063 | 0.92 | AR (0.87) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL547391 | 0.90 | AR (0.84) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL1715956 | 0.90 | AR (1.00) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL1716086 | 0.90 | AR (0.84) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL29094457 | 0.89 | AR (0.82) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL1715463 | 0.89 | AR (0.82) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL1715951 | 0.89 | AR (0.82) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL2633007 | 0.88 | AR (0.79) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL15362807 | 0.88 | AR (0.79) | ARABCG2HDAC1GABRPGABRD | |
| SCHEMBL21350025 | 0.88 | AR (0.79) | ARABCG2HDAC1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2444085-B1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | UNIV CALIFORNIA (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8648105-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-11 | — | — | US | disclosed |
| WO-2013067142-A1 | COMPOUNDS AND TREATMENT METHODS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2007127010-A9 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | AR 1/4885ABCG2 436/4885HDAC1 142/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | AR 2/4885ABCG2 3832/4885HDAC1 183/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | AR 1/4885ABCG2 4136/4885HDAC1 176/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885ABCG2 3832/4885HDAC1 183/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | AR 2292/4885ABCG2 3067/4885HDAC1 748/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885ABCG2 2587/4885HDAC1 1143/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | AR 11/4885ABCG2 4017/4885HDAC1 54/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885ABCG2 3583/4885HDAC1 2205/4885 |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | AR, SHBG, PTMS | AR 1/4885ABCG2 4430/4885HDAC1 1091/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885ABCG2 3832/4885HDAC1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.